CARLSBAD, Calif., July 17 Isis Pharmaceuticals,Inc. (Nasdaq: ISIS) announced today that Martin P. Bedigian, M.D. will joinIsis on August 18, 2008 as Vice President and Chief Medical Officer. In thisposition, Dr. Bedigian will take the lead and be responsible for all medicalaspects of Isis' clinical development programs.
"I look forward to joining the Isis team," said Dr. Bedigian. "Thecompany is on the forefront in so many areas of clinical development and hasthe financial strength to continue to grow an already large pipeline. I amvery eager and enthusiastic to become part of a team with the power ofantisense drugs to treat a wide variety of diseases."
Dr. Bedigian comes to Isis from Novartis Pharmaceuticals where he was theGlobal Head of the Cardiovascular Assessment Group, a center of excellenceresponsible for the cardiovascular aspects of projects and programs acrosstherapeutic areas and throughout research and development. During his tenureat Novartis, Dr. Bedigian was a lead member of Exploratory Development,Translational Medicine and the Integrated Safety Assessment Board.
"The executive team here at Isis is extraordinarily pleased that Dr.Bedigian is joining us. His appointment comes at a key time in our maturationwhen we have used antisense technology to create a very large and diverseportfolio of drugs. Martin's training and expertise across all of thetherapeutic areas of our pipeline will nicely complement our expanding drugdevelopment pipeline," commented Dr. Stanley T. Crooke, Chairmain and ChiefExective Officer of Isis Pharmaceuticals.
Dr. Bedigian received his Medical Degree from New York Medical College andcompleted his residency in Internal Medicine at Emory University. He servedfellowships in Hypertension and Non-invasive Cardiology at the VA MedicalCenter in Washington, D.C. as well as Nuclear Medicine at the University ofSouthern California and Emory University in the Department of Radiology andthe Division of Cardiology. Dr. Bedigian is widely published in cardiology andclinical trials medicine, and is a member of several important American HeartAssociation Expert panels.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop noveldrugs for its product pipeline and for its partners. The Company hassuccessfully commercialized the world's first antisense drug and has 18 drugsin development. Isis' drug development programs are focused on treatingcardiovascular and metabolic diseases. Isis' partners are developingantisense drugs invented by Isis to treat a wide variety of diseases. IbisBiosciences, Inc., Isis' majority-owned subsidiary, is developing andcommercializing the Ibis T5000(TM) Biosensor System, a revolutionary system toidentify infectious organisms. Isis is a joint owner of Regulus TherapeuticsLLC, a joint venture focused on the discovery, development andcommercialization of microRNA therapeutics. As an innovator in RNA-based drugdiscovery and development, Isis is the owner or exclusive licensee of over1,500 issued patents worldwide. Additional information about Isis isavailable at http://www.isispharm.com.
This press release includes forward-looking statements regarding IsisPharmaceuticals and the Company's business. Any statement describing Isis'goals, expectations, financial or other projections, intentions or beliefs isa forward-looking statement and should be considered an at-risk statement,including those statements that are described as Isis' goals. Such statementsare subject to certain risks and uncertainties, particularly those inherent inthe process of discovering, developing and commercializing drugs that are safeand effective for use as human therapeutics, and in the endeavor of building abusiness around such products. Isis' forward-looking statements also involveassumptions that, if they never materialize or prov